Targeted Oncology

Papers
(The H4-Index of Targeted Oncology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
An Overview of PARP Inhibitors for the Treatment of Breast Cancer217
Vaccine Therapies for Cancer: Then and Now130
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study83
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma61
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features47
PARP Inhibitors in Ovarian Cancer: A Review45
The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy39
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort28
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting26
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer25
Isatuximab: A Review of Its Use in Multiple Myeloma24
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer24
The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges24
Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib22
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis22
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib21
Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study21
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study21
Durvalumab: A Review in Extensive-Stage SCLC21
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia19
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC19
0.038532972335815